Skip to main content

TSLP Antibody (tezepelumab)

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28453

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

ELISA, Flow Cytometry, Functional

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Human IgG2 Clone # tezepelumab

Concentration

LYOPH mg/ml

Product Specifications

Immunogen

TSLP

Reactivity Notes

Predicted species reactivity: Cynomolgus

Clonality

Monoclonal

Host

Human

Isotype

IgG2

Endotoxin Level

< 0.001EU/ug,determined by LAL method.

Description

Expressed from CHO. The heavy chain type is huIgG2, and the light chain type is hulambda. It has a predicted MW of 145.5 kDa.

Also known as 'tezepelumab'.

Upon receipt, store immediately at -20C or lower for 24 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.

Scientific Data Images for TSLP Antibody (tezepelumab)

TSLP Antibody (tezepelumab)

ELISA: TSLP Antibody (tezepelumab)[NBP3-28453] -

Immobilized human TSLP His at 2 ug/mL can bind TSLP Antibody (tezepelumab), EC50=0.0518 ug/mL.
TSLP Antibody (tezepelumab)

In vivo assay: TSLP Antibody (tezepelumab)[NBP3-28453] -

Tezepelumab reduced levels of IL13 in BALF of OVA asthma model on B-hTSLP/hTSLPR mice. The result showed significant IL13 inhibition effects at 15 mpk.
TSLP Antibody (tezepelumab)

Flow Cytometry: TSLP Antibody (tezepelumab)[NBP3-28453] -

TSLP Antibody (tezepelumab)-induced FACS Blocking activity was evaluated using TSLPR/IL7R-CHO-K. The IC50 was approximately 0.0802 ug/mL.

Applications for TSLP Antibody (tezepelumab)

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Functional

Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Reconstitution

Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

Formulation

Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)

Preservative

No Preservative

Concentration

LYOPH mg/ml

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C.

Background: TSLP

Thymic stromal lymphopoietin (TSLP) has recently been identified as an important factor capable of driving dendritic cell maturation and activation. TSLP is a four-helix-bundle cytokine that is expressed mainly by barrier epithelial cells and is a potent activator of several cell types such as myeloid dendritic cells. TSLP is involved in the positive selection of regulatory T cells, maintenance of peripheral CD4+ T cell homeostasis and the induction of CD4+ T cell-mediated allergic reaction. TSLP is also capable of supporting the growth of fetal liver and adult B cell progenitors and their differentiation to the IgM-positive stage of B cell development. Amino acid sequence analysis has shown poor homology between human and mouse TSLP although they exhibit similar biological functions and are expressed in similar tissues. Despite its predicted molecular weight, TSLP often migrates at a higher molecular weight in SDS-PAGE. At least two differentially spliced isoforms of TSLP are known to exist.

Long Name

Thymic Stromal Lymphopoietin

Alternate Names

thymic stromal lymphopoietin

Gene Symbol

TSLP

UniProt

Additional TSLP Products

Product Documents for TSLP Antibody (tezepelumab)

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for TSLP Antibody (tezepelumab)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...